Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
TNDM - Tandem Diabetes Care, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.69
DETAILS
HIGH:
$55.00
LOW:
$21.00
MEDIAN:
$28.00
CONSENSUS:
$31.69
UPSIDE:
111.76%
Stock News
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Tandem Diabetes beats Q1 revenue and earnings estimates as gross margin expands, but shares decline 23.6% after the results announcement.
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tandem Diabetes Care (TNDM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care Q1 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product launches.
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.67 per share a year ago.
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026. First Quarter 2026 Financial and Strategic Highlights Achieved record first quarter pump shipments, sales and gross margin: Shipments of more than 29,000 pumps worldwide, including 19,000 pumps in the United States Sales o.
Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type 1 diabetes.
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.8% -- What GF Score of 74 Tells Investors
On April 13, 2026, Tandem Diabetes Care Inc (TNDM) shares rose 4.8% today, bringing the current price to $20.10. Despite today's increase, the stock has fluctua
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diabetes.
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. , (“ Tandem " or the "Company") ( NASDAQ:TNDM ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of “Hold” from Analysts
Shares of Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report) have been assigned a consensus rating of "Hold" from the nineteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, eight have given a buy recommendation and one
Assenagon Asset Management S.A. Invests $26.99 Million in Tandem Diabetes Care, Inc. $TNDM
Assenagon Asset Management S.A. purchased a new position in Tandem Diabetes Care, Inc. (NASDAQ: TNDM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,227,856 shares of the medical device company's stock, valued at approximately $26,988,000. Assenagon Asset Management S.A.
Tandem Diabetes Care Maps Pharmacy Shift, Targets 65% Gross Margin and 2026 Mobi Tubeless Launch
Executives from Tandem Diabetes Care (NASDAQ: TNDM) outlined how a shift toward the pharmacy channel, an expanding product portfolio, and international buildout are expected to reshape the company's revenue mix and margin profile over the next several years during an investor discussion hosted by Oppenheimer medical device analyst Suraj Kalia. Pharmacy channel seen as near-term margin
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bullish Call On Tandem Diabetes Signals Long-Term Growth Confidence
Tandem Diabetes Care Inc. (NASDAQ: TNDM) stock is trading higher on Tuesday following an analyst upgrade, citing a long-term upside opportunity.
Tandem Diabetes Care, Inc. $TNDM Stock Position Raised by ArrowMark Colorado Holdings LLC
ArrowMark Colorado Holdings LLC lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) by 36.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,691,198 shares of the medical device company's stock after purchasing an additional 991,649 shares during the
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now
New pump launches, CGM integrations and strong solvency support Tandem Diabetes' growth outlook, though intense competition and macro headwinds remain risks.
Price Targets
Tandem Diabetes price target lowered to $55 from $56 at Barclays
$55.00
(was $15.48)
Barclays
Tandem Diabetes price target raised to $24 from $22 at Mizuho
$24.00
(was $18.47)
Anthony Petrone
·
Mizuho Securities
Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn
$45.00
(was $20.68)
Issie Kirby
·
Redburn Partners
Tandem Diabetes price target raised to $27 from $24 at Truist
$27.00
(was $24.57)
Truist Financial
Tandem Diabetes upgraded to Buy from Hold at Lake Street
$50.00
(was $24.57)
Lake Street
Tandem Diabetes price target raised to $28 from $25 at Goldman Sachs
$28.00
(was $24.57)
David Roman
·
Goldman Sachs
Tandem Diabetes price target raised to $56 from $55 at Barclays
$56.00
(was $24.57)
Matt Miksic
·
Barclays
Tandem Diabetes price target raised to $22 from $21 at Mizuho
$22.00
(was $18.52)
Mizuho Securities
Tandem Diabetes price target raised to $22 from $20 at Stifel
$22.00
(was $18.52)
Stifel Nicolaus
Tandem Diabetes price target raised to $22 from $17 at UBS
$22.00
(was $18.52)
UBS
Tandem Diabetes price target raised to $21 from $14 at Piper Sandler
$21.00
(was $18.52)
Matt O'Brien
·
Piper Sandler
Tandem Diabetes price target raised to $20 from $16 at Stifel
$20.00
(was $19.11)
Stifel Nicolaus
Tandem Diabetes price target raised to $25 from $16 at Goldman Sachs
$25.00
(was $22.50)
David Roman
·
Goldman Sachs
Tandem Diabetes price target raised to $24 from $17 at Truist
$24.00
(was $22.22)
Truist Financial
Tandem Diabetes price target raised to $30 from $25 at RBC Capital
$30.00
(was $22.81)
RBC Capital
Tandem Diabetes price target raised to $35 from $24 at Canaccord
$35.00
(was $22.60)
William Plovanic
·
Canaccord Genuity
Tandem Diabetes price target raised to $21 from $18 at Mizuho
$21.00
(was $22.60)
Anthony Petrone
·
Mizuho Securities
Tandem Diabetes upgraded to Outperform from Neutral at Baird
$30.00
(was $22.12)
Robert W. Baird
Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
$23.00
(was $20.51)
Morgan Stanley
Tandem Diabetes price target raised to $16 from $14 at Truist
$16.00
(was $15.11)
Richard Newitter
·
Truist Financial